IP Library Granted Patent US 7,148,242
Granted Patent B2
US 7,148,242 · App. 10/171,706 · Granted Dec 12, 2006

N-formyl hydroxylamine compounds, compositions and methods of use

Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,148,242
App. No.
10/171,706
Granted
Dec 12, 2006
Kind
B2
Abstract

N-[1-oxo-2-alkyl-3-(N-hydroxyformamido)-propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo 4-7 alkanes or thiazacyclo 4-7 alkanes or imidazacyclo 4-7 alkanes have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by peptidyl deformylase inhibitors such as treatment of bacterial infections.

Claims (54)

1. The compound of formula (I)

wherein X is —CH 2 —, —S—, —CH(OH)—, —CH(OR)—, —CH(SH)—, —CH(SR)—, —CF 2 —, —C═N(OR)— or —CH(F)—;

R is alkyl;

R 1 is heteroaryl or aryl;

Each of R 2 , R 3 , R 4 and R 5 is independently hydrogen or alkyl, or (R 2 or R 3 ) and (R 4 or R 5 ) collectively form a C 4-7 cycloalkyl; and

n is 0 to 3, provided that when n is 0, X is —CH 2 —;

a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. The compound of formula (I) according to claim 1 , wherein R 1 is heteroaryl, X is —CH 2 —, —CH(OH)—, —CH(OR)—, —CF 2 — or —CH(F)—, R 2 , R 3 and R 4 are hydrogen, R 5 is alkyl and n is 1;

a pharmaceutically acceptable salt thereof or a prodrug thereof.

3. The compound of formula (I) according to claim 1 , wherein the heteroaryl is of formula (II)

wherein R 6 , R 7 , R 8 and R 9 are independently hydrogen, alkyl, substituted alkyl, hydroxyl, alkoxy, acyl, acyloxy, carboxyalkyl, thiocyanate, halogen, cyano, nitro, thioalkoxy, phenyl, heteroalkylaryl, alkylsulfonyl, or formyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

4. The compound of formula (I) according to claim 3 , wherein the heteroaryl of formula (II) is

wherein R 6 , R 7 , R 8 and R 9 are as defined in claim 4 ; a pharmaceutically acceptable salt thereof or a prodrug thereof.

5. The compound of formula (I) according to claim 1 , wherein R 6 is nitro, alkyl, substituted alkyl, phenyl, hydroxyl, formyl, heteroalkylaryl, alkoxy, acyl, or acyloxy; and R 7 , R 8 , and R 9 are hydrogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

6. The compound of formula (I) according to claim 5 , wherein R 6 is alkyl, substituted alkyl, hydroxyl or alkoxy; a pharmaceutically acceptable salt thereof or a prodrug thereof.

7. The compound of formula (I) according to claim 1 , wherein R 6 , R 8 and R 9 are hydrogen, and R 7 is alkyl, substituted alkyl, phenyl, halogen, alkoxy or cyano; a pharmaceutically acceptable salt thereof or a prodrug thereof.

8. The compound of formula (I) according to claim 7 , wherein R 7 is alkyl, substituted alkyl or alkoxy; a pharmaceutically acceptable salt thereof or a prodrug thereof.

9. The compound of formula (I) according to claim 1 , wherein R 6 , R 7 , R 9 are hydrogen and R 8 is alkyl, substituted alkyl, halogen, nitro, cyano, thioalkoxy, acyloxy, phenyl, alkylsulfonyl or carboxyalkyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

10. The compound of formula (I) according to claim 9 , wherein R 8 is alkyl, substituted alkyl, halogen or carboxyalkyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

11. The compound of formula (I) according to claim 1 , wherein R 6 , R 7 , R 8 are hydrogen and R 9 is alkyl, halogen or hydroxyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

12. The compound of formula (I) according to claim 1 , wherein R 7 and R 9 are hydrogen, and R 6 and R 8 are independently halogen, alkyl, substituted alkyl, phenyl or cyano; a pharmaceutically acceptable salt thereof or a prodrug thereof.

13. The compound of formula (I) according to claim 1 , wherein R 7 and R 9 are independently alkyl or substituted alkyl and R 6 and R 8 are hydrogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

14. The compound of formula (I) according to claim 1 , wherein R 6 and R 9 are hydrogen, R 7 is alkyl or substituted alkyl and R 8 is nitro; a pharmaceutically acceptable salt thereof or a prodrug thereof.

15. The compound of formula (I) according to claim 1 , wherein R 8 and R 9 are hydrogen, R 6 is cyano, and R 7 is alkoxy; a pharmaceutically acceptable salt thereof or a prodrug thereof.

16. The compound of formula (I) according to claim 1 , wherein R 7 and R 8 are hydrogen and R 6 is alkyl, substituted alkyl, alkoxy or thiocyanate and R 9 is alkyl or substituted alkyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

17. The compound of formula (I) according to claim 1 , wherein R 6 and R 7 are hydrogen, R 8 is nitro or halogen and R 9 is alkyl or substituted alkyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

18. The compound of formula (I) according to claim 1 , wherein R 6 , R 7 , R 8 and R 9 are hydrogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

19. The compound of formula (I) according to claim 1 , wherein R 6 and R 7 combine to form phenyl and R 8 and R 9 are hydrogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

20. The compound of formula (I) according to claim 1 , wherein R 6 and R 7 are hydrogen and R 8 and R 9 combine to form phenyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

21. The compound of formula (I) according to claim 20 , wherein the phenyl is substituted with hydroxyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

22. The compound of formula (I) according to claim 1 , wherein n is 0; a pharmaceutically acceptable salt thereof or a prodrug thereof.

23. The compound of formula (I) according to claim 22 , wherein R 6 , R 7 , R 8 and R 9 are independently hydrogen, alkyl or halogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

24. The compound of formula (I) according to claim 23 , wherein R 6 , R 7 , R 8 and R 9 are hydrogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

25. The compound of formula (I) according to claim 23 , wherein R 6 , R 8 and R 9 are hydrogen and R 7 is alkyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

26. The compound of formula (I) according to claim 23 , wherein R 6 , R 7 and R 9 are hydrogen and R 8 is alkyl or halogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

27. The compound according to claim 3 , wherein the heteroaryl is of formula (II)

wherein R 6 , R 7 , R 8 and R 9 are as defined in claim 4 ;

a pharmaceutically acceptable salt thereof or a prodrug thereof.

28. The compound of formula (II) according to claim 27 , wherein R 7 and R 8 combine to form phenyl and R 6 and R 9 are hydrogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

29. The compound of formula (I) according to claim 1 , wherein the heteroaryl is of formula (III)

wherein R 6 , R 7 , R 8 % and R 9 are independently hydrogen, alkyl, substituted alkyl, phenyl, halogen, hydroxyl or alkoxy; a pharmaceutically acceptable salt thereof or a prodrug thereof.

30. The compound of formula (I) according to claim 29 , wherein the heteroaryl is of the formula (III)

wherein R 6 , R 7 , R 8 and R 9 are as defined in claim 29 ; a pharmaceutically acceptable salt thereof or a prodrug thereof.

31. The compound of formula (III) according to claim 29 , wherein R 6 and R 8 are hydrogen, R 9 is hydrogen or alkyl and R 7 is alkyl, substituted alkyl or phenyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

32. The compound of formula (III) according to claim 29 , wherein R 6 , R 7 and R 9 are hydrogen and R 8 is halogen, alkyl or substituted alkyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

33. The compound of formula (III) according to claim 29 , wherein R 7 , R 8 and R 9 are hydrogen and R 6 is hydroxyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

34. The compound of formula (I) according to claim 1 , wherein R 1 is substituted or unsubstituted phenyl; a pharmaceutically acceptable salt thereof or a prodrug thereof.

35. The compound of formula (I) according to claim 34 , wherein the phenyl is substituted with an alkoxy or aryloxy group; a pharmaceutically acceptable salt thereof or a prodrug thereof.

36. The compound of formula (I) according to claim 1 , wherein the heteroaryl is of formula (IV)

wherein R 10 and R 11 are independently hydrogen or halogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

37. The compound of formula (IV) according to claim 36 , wherein R 10 and R 11 are both hydrogen or both halogen; a pharmaceutically acceptable salt thereof or a prodrug thereof.

38. A compound according to claim 1 , wherein the compound is selected from the group consisting of 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid-(5-methyl-pyridin-2-yl)-amide, 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid-(5-trifluoromethyl-pyridin-2-yl)-amide, 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl }-pyrrolidine-2-S-carboxylic acid-(6-fluoro-pyridin-2-yl)-amide, 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid-(4-ethyl-pyridin-2-yl)-amide, 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid (3-hydroxy-pyridin-2-yl)-amide, 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid-(5-trifluoromethyl-1-oxy-pyridin-2-yl)-amide, 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid-(4-ethyl-1-oxy-pyridin-2-yl)-amide, 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid-(3-methoxy-6-methyl-pyridin-2-yl)-amide, 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid (4-methoxy-pyridin-2-yl)-amide and 1-{2-R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2-S-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; a pharmaceutically acceptable salt of any said compound or a prodrug of any said compound.

39. A pharmaceutical composition comprising a compound of formula (I), a pharmaceutically acceptable salt thereof or a prodrug thereof according to claim 1 , and a pharmaceutically acceptable carrier.

40. The pharmaceutical composition according to claim 39 , wherein the composition further includes another therapeutic agents selected from the group consisting of other antibacterial agents, anti-inflammatory agents and analgesics.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2010
From: VICURON PHARMACEUTICALS INC.
To: VICURON HOLDINGS LLC
Reel/Frame 023720/0776 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2008
From: ALVAREZ, SALVADOR GARCIA; JACOBS, JEFFREY; JAIN, RAKESH K.; PATEL, DINESH V.; YUAN, ZHENGYU
To: VERSICOR, INC.
Reel/Frame 020874/0242 →
MERGER Recorded Mar 21, 2005
From: VERSICOR INC.
To: VICURON PHARMACEUTICALS INC.
Reel/Frame 016385/0281 →
Continuity (3)
Provisional Application 6036031300 · Feb 27, 2002
Provisional Application 6029841900 · Jun 15, 2001
Related Publication 20030045479A1 · Mar 6, 2003